Literature DB >> 21284523

Replication of the primary dog kidney-53 dengue 2 virus vaccine candidate in Aedes aegypti is modulated by a mutation in the 5' untranslated region and amino acid substitutions in nonstructural proteins 1 and 3.

Aaron C Brault1, Richard M Kinney, Payal D Maharaj, Emily N G Green, William K Reisen, Claire Y-H Huang.   

Abstract

Previous studies have demonstrated reduced replication of the cell culture-adapted Dengue-2 virus (DENV-2) vaccine candidate, primary dog kidney (PDK)-53, compared with the parental DENV-2 strain, 16681, in C6/36 cells. Various DENV-2 mutants incorporating PDK-53 substitutions singly and in combination into the 16681 genetic backbone were used to identify the genetic basis for impaired replication of the vaccine candidate in vitro in Aedes aegypti cell culture (Aag2 cells) as well as the reduced in vivo infectivity and transmissibility within Ae. aegypti infected by intrathoracic inoculation. 5' untranslated region (UTR-c57t) and nonstructural protein 1 (NS1-G53D) mutations were required to completely attenuate in vitro replication. In contrast, incorporation of the PDK-53-specific NS3-250V mutation into the 16681 virus resulted in reduced replication in mosquitoes but had no effect on in vitro replication. Further, reversion of the PDK-53 NS3-250 site to that of the wild-type 16681 virus (NS3-V250E) failed to increase either in vitro or in vivo replication. Intrathoracic inoculation of Ae. aegypti with mutants containing the PDK-53 NS1 substitution exhibited in vivo replication indistinguishable from the parental PDK-53 virus, implicating this mutation as the dominant determinant for impaired mosquito replication of the PDK-53 candidate; however, further attenuation of in vivo replication was magnified in mutants including the additional 5'UTR-c57t mutation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21284523     DOI: 10.1089/vbz.2010.0150

Source DB:  PubMed          Journal:  Vector Borne Zoonotic Dis        ISSN: 1530-3667            Impact factor:   2.133


  11 in total

1.  Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.

Authors:  Jorge E Osorio; Joseph N Brewoo; Shawn J Silengo; John Arguello; Ioana R Moldovan; Magdalena Tary-Lehmann; Tim D Powell; Jill A Livengood; Richard M Kinney; Claire Y-H Huang; Dan T Stinchcomb
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  Structural gene (prME) chimeras of St Louis encephalitis virus and West Nile virus exhibit altered in vitro cytopathic and growth phenotypes.

Authors:  Payal D Maharaj; Michael Anishchenko; Stanley A Langevin; Ying Fang; William K Reisen; Aaron C Brault
Journal:  J Gen Virol       Date:  2011-09-21       Impact factor: 3.891

3.  Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by Aedes albopictus.

Authors:  Elizabeth A Dietrich; Yee Tsuey Ong; Janae L Stovall; Hansi Dean; Claire Y-H Huang
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

4.  Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.

Authors:  Sarah L George; Mimi A Wong; Tina J T Dube; Karen L Boroughs; Janae L Stovall; Betty E Luy; Aurelia A Haller; Jorge E Osorio; Linda M Eggemeyer; Sharon Irby-Moore; Sharon E Frey; Claire Y-H Huang; Dan T Stinchcomb
Journal:  J Infect Dis       Date:  2015-03-19       Impact factor: 5.226

5.  Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.

Authors:  Jorge E Osorio; Ivan D Velez; Cynthia Thomson; Liliana Lopez; Alejandra Jimenez; Aurelia A Haller; Shawn Silengo; Jaclyn Scott; Karen L Boroughs; Janae L Stovall; Betty E Luy; John Arguello; Mark E Beatty; Joseph Santangelo; Gilad S Gordon; Claire Y-H Huang; Dan T Stinchcomb
Journal:  Lancet Infect Dis       Date:  2014-07-23       Impact factor: 25.071

6.  Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization.

Authors:  William B Messer; Boyd Yount; Kari E Hacker; Eric F Donaldson; Jeremy P Huynh; Aravinda M de Silva; Ralph S Baric
Journal:  PLoS Negl Trop Dis       Date:  2012-02-28

7.  Population structure of the dengue viruses, Aragua, Venezuela, 2006-2007. Insights into dengue evolution under hyperendemic transmission.

Authors:  Rosmari Rodriguez-Roche; Elci Villegas; Shelley Cook; Pauline A W Poh Kim; Yoandri Hinojosa; Delfina Rosario; Iris Villalobos; Herminia Bendezu; Martin L Hibberd; Maria G Guzman
Journal:  Infect Genet Evol       Date:  2011-12-17       Impact factor: 3.342

8.  Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).

Authors:  Claire Y-H Huang; Richard M Kinney; Jill A Livengood; Bethany Bolling; John J Arguello; Betty E Luy; Shawn J Silengo; Karen L Boroughs; Janae L Stovall; Akundi P Kalanidhi; Aaron C Brault; Jorge E Osorio; Dan T Stinchcomb
Journal:  PLoS Negl Trop Dis       Date:  2013-05-30

9.  Biological and phylogenetic characteristics of West African lineages of West Nile virus.

Authors:  Gamou Fall; Nicholas Di Paola; Martin Faye; Moussa Dia; Caio César de Melo Freire; Cheikh Loucoubar; Paolo Marinho de Andrade Zanotto; Ousmane Faye; Amadou Alpha Sall
Journal:  PLoS Negl Trop Dis       Date:  2017-11-08

Review 10.  Anti-dengue Vaccines: From Development to Clinical Trials.

Authors:  Josilene Ramos Pinheiro-Michelsen; Rayane da Silva Oliveira Souza; Itana Vivian Rocha Santana; Patrícia de Souza da Silva; Erick Carvalho Mendez; Wilson Barros Luiz; Jaime Henrique Amorim
Journal:  Front Immunol       Date:  2020-06-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.